• 8:30 - 18:00 M-T / 8.30 - 15.00 F

Histocell starts a clinical trial with its cell therapy drug HC016 in patients with ARDS due to COVID-19

Print

The most serious complication of COVID-19 infection is Acute Respiratory Distress Syndrome (ARDS). More than 40% of seriously hospitalised patients develop ARDS, and about 50% with moderate-severe ARDS die because of it. Taking into account the proven safety and efficacy of mesenchymal cells in diseases that occur with a process of exacerbated inflammation, several groups, including the one led by Dr. Dongcheng Wu in Wuhan (China), have focused their efforts on cell treatment for critically ill COVID-19 patients with promising results.

Continue Reading

Histocell signs an agreement with Bfactory Italia for the distribution of Reoxcare

Print

The company Bfactory Italia, specialised in the distribution of international medical devices in the Italian market, focuses its business in the search of natural products that improve people's lives.

For this reason, they have started with the distribution of Reoxcare line for wound healing.

Reoxcare, thanks to its innovative character and its components of natural origin, is a great example of the type of products the company wants to have in its porfolio.

Fbactory Italia website

Histocell took part in the 9th Congress of the Spanish Wound Society

Print

The ninth edition of the SEHER Congress was held in Madrid from March 27 to 29, with the aim of gathering all professionals dedicated to the management of different types of wounds.

Once again, we had the opportunity to continue making Reoxcare product known among those who still do not know it, as well as exchanging opinions with current customers.

Continue Reading

DEIA - Cosmética vasca, el "boom" de belleza

Print

Completamente alejada de la poción de un druida o de elixires mágicos, en una planta de Larrabetzu se elabora alta cosmética científica y tecnológica made in Euskadi.

Leer noticia completa

Histocell y Microdan alcanzan un acuerdo para reforzar la comercialización de Reoxcare en España

Print

Histocell, empresa biofarmacéutica de medicina regenerativa y Microdan, empresa especializada en seguridad del paciente, control de infección y tratamiento de heridas en hospitales, han sellado un acuerdo para colaborar en la comercialización de Reoxcare en España.

Continue Reading

Histocell will manufacture Enoc Pharma products at its new factory at Larrabetzu, Bizkaia

Print

Histocell has established a collaboration agreement with the Catalan firm Enoc Pharma, which will combine the technologies of both companies to develop and manufacture highly innovative medical devices and cosmetic products in Bizkaia. Under this agreement, Histocell will open a new product manufacturing line at its factory based on Advanced Liposome technology developed by Enoc Pharma. This is an important milestone for Histocell that realises how its commitment to manufacturing is backed within a few months of launching its production facility.

Continue Reading

Histocell Headquarters

Parque Tecnológico 801A, 2º
48160 Derio
Bizkaia - Spain

+34 94 656 7900
info@histocell.com

Histocell Factory

Polígono Sasine. Patakon s/n
48195 Larrabetzu
Bizkaia - Spain

+34 94 656 7900
info@histocell.com

Our mision

We develop new advanced therapy medicinal products, medical devices and dermocosmetics to improve people's quality of life.

Copyright © Histocell